How ALPHAEON's acquisition of Eveo will boost its technology foundation
ALPHAEON Corporation, a social commerce company and subsidiary to Strathspey Crown Holdings LLC, recently announced its acquisition of award-winning digital technology company Eveo.
Eveo has helped pioneer digital platforms in the healthcare space, including ALPHAEON's social commerce platform ShoutMD, for over 16 years. ShoutMD allows board certified physician specialists to share insights, collaborate on new ideas and purchase lifestyle healthcare products with the click of a button under a broad affinity program.
With this acquisition, ALPHAEON boosts its internal social commerce development and design capabilities and expertise.
"Eveo is a leader in social commerce development and an important addition to ALPHAEON as we expand and scale our ShoutMD platform for global growth," said ALPHAEON CEO Robert E. Grant. "With this acquisition, we continue to gain deep expertise in both design and development of advanced social commerce platforms and information systems. This transaction increases our software and technology teams, paving the way for our continued and rapid commercial growth.”
RELATED TOPIC: Top 5 digital health giants you should be watching
A leading independent, full-service health and wellness company rooted in technology, Eveo has partnered with over 200 health brands to help them achieve their goals through insight-driven strategies, award-winning, creative, and groundbreaking innovations.
Meanwhile, ALPHAEON Corporation is a social commerce company with the goal of transforming lifestyle healthcare by bringing to market highly innovative products and services to promote consumer wellness, beauty and performance. The company works in partnership with board certified physicians ensuring access to leading advancements in lifestyle healthcare.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”